January 2017:
Coverage began for Type 1 diabetes patients requiring intensive insulin management.
Continuous Glucose Monitor (CGM) Coverage Timeline
March 2018:
Extended to Type 2 diabetes patients on intensive insulin therapy with documented hypoglycemia episodes.
July 2021:
Included patients using inhaled insulin, broadening access beyond those on multiple daily injections.
April 2022:
Further expanded to all insulin-injecting diabetics, regardless of injection frequency.
April 2023:
Coverage now includes non-insulin-using patients with documented severe hypoglycemia requiring clinical intervention.
2025 - Onward:
Projections suggest coverage may extend to all diabetes patients, including those with prediabetes or gestational diabetes, to support proactive glucose management.
